Citation:Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, et al 2013

From Cancer Guidelines Wiki

Citation


Garassino MC, Martelli O, Broggini M, Farina G, Veronese S, Rulli E, et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol 2013 Sep;14(10):981-8 Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/23883922.



Critical appraisals

Critical appraisal linkClinical questionAssigned toStatus
What is the optimal systemic therapy regimen for patients with poor performance status for treatment of stage IV inoperable NSCLC?Assoc. Prof. Nick Pavlakiscompleted
Which new agent or platinum combination regimen is best for treatment of stage IV inoperable NSCLC?Assoc. Prof. Nick Pavlakiscompleted
Is monotherapy with new third generation (3G) agents as effective as platinum combination therapy for treatment of stage IV inoperable NSCLC?Assoc. Prof. Nick Pavlakiscompleted
What is the optimal systemic therapy regimen for patients with oncogenic driver mutations (including EGFR and ALK)?Assoc. Prof. Nick Pavlakiscompleted

Compare quality appraisals for each clinical question

Cited by

  1. What is the optimal second-line therapy in patients with stage IV inoperable NSCLC?